AZIDUS BRASIL PESQUISA CIENTIFICA E DESENVOLVIMENTO LTDA

🇧🇷Brazil
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety of UFRJvac, Trivalent COVID-19 Vaccine

Not yet recruiting
Conditions
Healthy People
First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
Azidus Brasil
Target Recruit Count
156
Registration Number
NCT06303635

Efficacy and Safety and Pharmacokinetics of Boya IVIG

Phase 3
Not yet recruiting
Conditions
Primary Immunodeficiency Disease
Interventions
Biological: Boya IVIG
First Posted Date
2023-11-29
Last Posted Date
2023-11-29
Lead Sponsor
Azidus Brasil
Target Recruit Count
50
Registration Number
NCT06150833

Efficacy and Safety of NestaCell® in Huntington's Disease

Phase 3
Not yet recruiting
Conditions
Huntington Disease
Interventions
Genetic: NestaCell®
First Posted Date
2023-10-24
Last Posted Date
2023-10-24
Lead Sponsor
Azidus Brasil
Target Recruit Count
120
Registration Number
NCT06097780

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Phase 3
Not yet recruiting
Conditions
Primary Immunodeficiency Disease
Interventions
Biological: IVIG
First Posted Date
2023-10-18
Last Posted Date
2024-03-12
Lead Sponsor
Azidus Brasil
Target Recruit Count
50
Registration Number
NCT06089122

Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

Phase 4
Completed
Conditions
Signs and Symptoms, Digestive
Interventions
Drug: Probiatop
Other: Placebo
First Posted Date
2022-11-02
Last Posted Date
2024-03-25
Lead Sponsor
Azidus Brasil
Target Recruit Count
150
Registration Number
NCT05603403
Locations
🇧🇷

A2Z Clinical Centro Avancado de Pesquisa Clinica Eireli, Valinhos, São Paulo, Brazil

Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine

First Posted Date
2022-09-15
Last Posted Date
2022-09-15
Lead Sponsor
Azidus Brasil
Target Recruit Count
300
Registration Number
NCT05542693

Study To Evaluate The Sensitivity Of The Linda Thermal Device

Recruiting
Conditions
Mammography
Thermography
Device
First Posted Date
2021-08-17
Last Posted Date
2022-10-27
Lead Sponsor
Azidus Brasil
Target Recruit Count
500
Registration Number
NCT05009277
Locations
🇧🇷

Hospital Vera Cruz, Campinas, São Paulo, Brazil

Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients

Phase 2
Withdrawn
Conditions
covid19
Interventions
Drug: Nitazoxanide
Drug: Placebo
First Posted Date
2020-06-22
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Registration Number
NCT04441398

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19

Phase 2
Withdrawn
Conditions
covid19
Interventions
Drug: Placebo
Drug: Nitazoxanide
First Posted Date
2020-06-17
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Registration Number
NCT04435314

Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

Phase 3
Recruiting
Conditions
covid19
Interventions
Drug: Placebo
Drug: Nitazoxanide
First Posted Date
2020-06-09
Last Posted Date
2022-10-31
Lead Sponsor
Azidus Brasil
Target Recruit Count
380
Registration Number
NCT04423861
Locations
🇧🇷

Hospital Vera Cruz, Campinas, São Paulo, Brazil

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy